Literature DB >> 33001280

Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome.

Márcio Tavares1, Sérgio Chacim2, José Mário Mariz2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33001280     DOI： 10.1007/s00277-020-04291-0

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  9 in total

1.  Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure.

Authors:  Vu H Duong; Karen Lin; Tea Reljic; Ambuj Kumar; Najla H Al Ali; Jeffrey E Lancet; Alan F List; Rami S Komrokji
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-09-17

2.  Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents.

Authors:  Anne Sophie Kubasch; Freya Schulze; Aristoteles Giagounidis; Katharina S Götze; Jan Krönke; Katja Sockel; Jan Moritz Middeke; Fatiha Chermat; Silke Gloaguen; Martin Puttrich; Carmen Weigt; Doreen William; Pierre Fenaux; Richard F Schlenk; Christian Thiede; Sebastian Stasik; Anna Mies; Lionel Adès; Uta Oelschlägel; Uwe Platzbecker
Journal:  Leukemia       Date:  2019-12-03       Impact factor: 11.528

3.  A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS).

Authors:  David A Sallman; Rami S Komrokji; Kendra L Sweet; Qianxing Mo; Kathy L McGraw; Vu H Duong; Ling Zhang; Lisa Ann Nardelli; Eric Padron; Alan F List; Jeffrey E Lancet
Journal:  Leuk Res       Date:  2019-03-30       Impact factor: 3.156

4.  Hedgehog signaling maintains chemoresistance in myeloid leukemic cells.

Authors:  K C S Queiroz; R R Ruela-de-Sousa; G M Fuhler; H L Aberson; C V Ferreira; M P Peppelenbosch; C A Spek
Journal:  Oncogene       Date:  2010-08-30       Impact factor: 9.867

5.  FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia.

Authors:  Kelly J Norsworthy; Kunthel By; Sriram Subramaniam; Luning Zhuang; Pedro L Del Valle; Donna Przepiorka; Yuan-Li Shen; Christopher M Sheth; Chao Liu; Ruby Leong; Kirsten B Goldberg; Ann T Farrell; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2019-05-07       Impact factor: 12.531

6.  Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia.

Authors:  R F Schlenk; P Frech; D Weber; P Brossart; H-A Horst; D Kraemer; G Held; M Ringhoffer; A Burchardt; G Kobbe; K Götze; D Nachbaur; T Fischer; M Lübbert; H R Salih; H Salwender; G Wulf; E Koller; M Wattad; W Fiedler; S Kremers; H Kirchen; B Hertenstein; P Paschka; V I Gaidzik; V Teleanu; M Heuser; F Thol; K Döhner; J Krauter; A Ganser; H Döhner
Journal:  Leukemia       Date:  2017-01-18       Impact factor: 11.528

7.  Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.

Authors:  Jorge E Cortes; Florian H Heidel; Andrzej Hellmann; Walter Fiedler; B Douglas Smith; Tadeusz Robak; Pau Montesinos; Daniel A Pollyea; Pierre DesJardins; Oliver Ottmann; Weidong Wendy Ma; M Naveed Shaik; A Douglas Laird; Mirjana Zeremski; Ashleigh O'Connell; Geoffrey Chan; Michael Heuser
Journal:  Leukemia       Date:  2018-12-16       Impact factor: 11.528

8.  Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.

Authors:  Courtney D DiNardo; Caitlin R Rausch; Christopher Benton; Tapan Kadia; Nitin Jain; Naveen Pemmaraju; Naval Daver; Wendy Covert; Kayleigh R Marx; Morgan Mace; Elias Jabbour; Jorge Cortes; Guillermo Garcia-Manero; Farhad Ravandi; Kapil N Bhalla; Hagop Kantarjian; Marina Konopleva
Journal:  Am J Hematol       Date:  2017-12-23       Impact factor: 13.265

9.  Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells.

Authors:  Nobuaki Fukushima; Yosuke Minami; Seiji Kakiuchi; Yachiyo Kuwatsuka; Fumihiko Hayakawa; Catoriona Jamieson; Hitoshi Kiyoi; Tomoki Naoe
Journal:  Cancer Sci       Date:  2016-09-02       Impact factor: 6.716
  9 in total
  2 in total

1.  Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients.

Authors:  Andrius Zucenka; Kazimieras Maneikis; Birute Pugaciute; Ugne Ringeleviciute; Austeja Dapkeviciute; Linas Davainis; Guoda Daukelaite; Paulina Burzdikaite; Vytautas Staras; Laimonas Griskevicius
Journal:  Ann Hematol       Date:  2021-03-04       Impact factor: 3.673

Review 2.  Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia.

Authors:  Jiale Ma; Zheng Ge
Journal:  Bosn J Basic Med Sci       Date:  2021-08-01       Impact factor: 3.363
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.